Adjuvanted RSVPreF3 vaccine impact over 3 RSV seasons in older adults with comorbidities

Résumé fourni par la source

Background We explored the efficacy of AS01 E -adjuvanted respiratory syncytial virus prefusion F protein-based vaccine (adjuvanted RSVPreF3) in subpopulations of participants with underlying medical conditions in the multi-country, phase 3 AReSVi-006 trial (conducted May/2021-May/2024). Methods Medically stable ≥60-year-olds were 1:1-randomised to receive one adjuvanted RSVPreF3 or placebo dose pre-RSV season 1. In exploratory post-hoc analyses in subgroups of participants with underlying conditions (including COPD, asthma, diabetes, obesity [BMI≥30 kg·m −2 ]), we evaluated efficacy of one vaccine dose against RSV-related lower respiratory tract disease (RSV-LRTD), acute respiratory illness (RSV-ARI), and RSV-ARI-related complications ( e.g. , pneumonia, COPD/asthma exacerbation, cardiovascular events). We also evaluated (post-hoc) RSV-ARI-related systemic corticosteroid and antibiotics use in participants with COPD or asthma. Results The efficacy analyses comprised 12 468 vaccine and 12 498 placebo recipients. Efficacy against RSV-LRTD over three RSV seasons was similar among participants with COPD (75.1%, 95% CI: 40.2–91.4), asthma (65.8%, 31.0–84.7), diabetes (69.8%, 37.5–87.1), and obesity (74.1%, 56.4–85.5) as in the overall study population (62.9%, 97.5% CI: 46.7–74.8). Efficacy was also observed against RSV-ARI in these subgroups. Efficacy against RSV-ARI-related complications was 74.4% (95% CI: 11.2–95.2) in participants with COPD and 60.8% (−9.9–88.7) in those with asthma. Among participants with COPD, 15.4% (1.9–45.4) of RSV-ARI episodes in vaccine versus 22.4% (12.5–35.3) in placebo recipients were treated with systemic corticosteroids, and 46.2% (19.2–74.9) versus 56.9% (43.2–69.8) with antibiotics. Conclusions Post-hoc analyses of the AReSVi-006 trial suggest that adjuvanted RSVPreF3 may help prevent RSV-ARI, RSV-LRTD, and RSV-related complications in medically stable older adults with underlying medical conditions like COPD and asthma.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.